Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia

Jump to navigation Jump to search

Supraventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Among the Different Types of Supraventricular Tachycardia

Differentiating Supraventricular Tachycardia from Ventricular Tachycardia

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples

Chest X Ray

Echocardiography

Cardiac Catheterization

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

2015 ACC/AHA Guideline Recommendations

Acute Treatment of SVT of Unknown Mechanism
Ongoing Management of SVT of Unknown Mechanism
Ongoing Management of IST
Acute Treatment of Suspected Focal Atrial Tachycardia
Acute Treatment of Multifocal Atria Tachycardia
Ongoing Management of Multifocal Atrial Tachycardia
Acute Treatment of AVNRT
Ongoing Management of AVNRT
Acute Treatment of Orthodromic AVRT
Ongoing Management of Orthodromic AVRT
Asymptomatic Patients With Pre-Excitation
Management of Symptomatic Patients With Manifest Accessory Pathways
Acute Treatment of Atrial Flutter
Ongoing Management of Atrial Flutter
Acute Treatment of Junctional Tachycardia
Ongoing Management of Junctional Tachycardia
Acute Treatment of SVT in ACHD Patients
Ongoing Management of SVT in ACHD Patients
Acute Treatment of SVT in Pregnant Patients
Acute Treatment and Ongoing Management of SVT in Older Population

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia

CDC on Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia

Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia in the news

Blogs on Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia

Directions to Hospitals Treating Supraventricular tachycardia

Risk calculators and risk factors for Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]

Overview

Intravenous beta blockers, diltiazem, procainamide, or verapamil is reasonable for acute treatment in patients with symptomatic junctional tachycardia. Oral beta blockers, diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia. Flecainide or propafenone may be reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have junctional tachycardia. Catheter ablation may be reasonable in patients with junctional tachycardia when medical therapy is not effective or contraindicated.[1]

Management of Junctional Tachycardia

2015 AHA recommendations for the management of junctional tachycardia are described below:[1]

Acute Treatment of Junctional Tachycardia

Class IIa
"1. Intravenous beta blockers are reasonable for acute treatment in patients with symptomatic junctional tachycardia "(Level of Evidence:C-LD ) "
"2. Intravenous diltiazem, procainamide, or verapamil is reasonable for acute treatment in patients with junctional tachycardia "(Level of Evidence:C-LD ) "

Management of ongoing Junctional Tachycardia

Class IIa
"1. Oral beta blockers are reasonable for ongoing management in patients with junctional tachycardia "(Level of Evidence:C-LD) "
"2. Oral diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia "(Level of Evidence:C-LD) "
Class IIb
"1. Flecainide or propafenone may be reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have junctional tachycardia "(Level of Evidence:C-LD) "
"2. Catheter ablation may be reasonable in patients with junctional tachycardia when medical therapy is not effective or contraindicated "(Level of Evidence:C-LD) "

References

  1. 1.0 1.1 Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ; et al. (2016). "2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol. 67 (13): e27–e115. doi:10.1016/j.jacc.2015.08.856. PMID 26409259.